Added to YB: 2024-07-05
Pitch date: 2024-07-04
MEDXF [bullish]
Medexus Pharmaceuticals Inc.
+42.38%
current return
Author Info
Stock Spin-Off Investing is a former equity and PE researcher who shares spin-off related content. Visit the website.
Company Info
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.
Market Cap
CAD 35.0M
Pitch Price
CAD 1.51
Price Target
10.00 (+365%)
Dividend
N/A
Sector
Pharmaceuticals
Category
special_situation
Stock Spin-off Investing: Buy Medexus Pharma
MEDXF: 2x FCF, 5.2x EBITDA, 2.2x net debt/EBITDA. FDA decision on Treosulfan by Oct 30; approval could double rev, triple EBITDA/FCF in 3yrs. Insiders own 10%+, buying more. $10 PT if approved (5.3x EV/EBITDA on $60M EBITDA). Limited downside due to cheap valuation, stable biz, Q1 2025 terbinafine catalyst ($20-30M/yr opportunity).
Read full article (1 min)